EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, VBI Vaccines's Enterprise Value is $45.68 Mil.
VBI Vaccines's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-61.75 Mil. Therefore, VBI Vaccines's EV-to-FCF for today is -0.74.
The historical rank and industry rank for VBI Vaccines's EV-to-FCF or its related term are showing as below:
VBIV'
s EV-to-FCF Range Over the Past 10 Years
Min: -46.86 Med: -5.12 Max: -0.34
Current: -0.74
During the past 13 years, the highest EV-to-FCF of VBI Vaccines was -0.34. The lowest was -46.86. And the median was -5.12.
VBIV's EV-to-FCF is ranked worse than 100% of 390
companies
in the Biotechnology industry
Industry Median: 4.475
vs VBIV: -0.74
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for VBI Vaccines's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of VBI Vaccines's EV-to-FCF
For the Biotechnology subindustry, VBI Vaccines's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VBI Vaccines's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, VBI Vaccines's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where VBI Vaccines's EV-to-FCF falls into.
VBI Vaccines EV-to-FCF Calculation
VBI Vaccines's EV-to-FCF for today is calculated as:
VBI Vaccines's current Enterprise Value is $45.68 Mil.
VBI Vaccines's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-61.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VBI Vaccines (NAS:VBIV) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
VBI Vaccines's PE Ratio for today is calculated as:
VBI Vaccines's share price for today is $0.574.
VBI Vaccines's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.414.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
VBI Vaccines EV-to-FCF Related Terms
Thank you for viewing the detailed overview of VBI Vaccines's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
VBI Vaccines Inc is a US-based commercial-stage, the biopharmaceutical company which is engaged in developing next-generation vaccines to address unmet needs in infectious disease and immuno-oncology. The company manufactures Sci-B-Vac product which is a hepatitis B (HBV) vaccine for adults, children, and newborns. Its products include Virus-Like Particle which is vaccine platform which allows for the design of enveloped virus-like particle vaccines that closely mimic the target viruses. The company operates through the single segment being Developing vaccines to address unmet needs in infectious disease and immuno-oncology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VBIV has been successfully added to your 